Cargando…

Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

BACKGROUND: High morbidity and mortality due to carbapenem-resistant Gram-negative bacilli (CR-GNB) has led to the resurgence of polymyxin B (PMB) use in the last decade. The aim of our multicenter, real-world study was to evaluate the effectiveness and safety of PMB in the treatment of CR-GNB infec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaojuan, Qi, Shaoyan, Duan, Xiaoguang, Han, Bing, Zhang, Shuguang, Liu, Shaohua, Wang, Haixu, Zhang, Haibo, Sun, Tongwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520283/ https://www.ncbi.nlm.nih.gov/pubmed/34656132 http://dx.doi.org/10.1186/s12967-021-03111-x

Ejemplares similares

An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria
por: Yang, Jing, et al.
Publicado: (2022)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children
por: Jia, Xuedong, et al.
Publicado: (2022)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial
por: Liu, Shaohua, et al.
Publicado: (2023)

Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
por: Xia, G. L., et al.
Publicado: (2021)

Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wang, Peile, et al.
Publicado: (2020)

Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections
por: Wu, Xiao-Li, et al.
Publicado: (2022)

Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study
por: Cai, Yiying, et al.
Publicado: (2020)

Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection
por: Wang, Peile, et al.
Publicado: (2023)

Coarse-grained simulations uncover Gram-negative bacterial defense against polymyxins by the outer membrane
por: Jiang, Xukai, et al.
Publicado: (2021)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections
por: Lu, Qiong, et al.
Publicado: (2021)

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens
por: Tran, Thien B., et al.
Publicado: (2018)

Treatment of Carbapenem-Resistant Multidrug-Resistant Gram-Negative Bacilli with Intracerebroventricular Injection of Polymyxin B: A Retrospective Study
por: Liu, Dongsheng, et al.
Publicado: (2022)

Analysis of mRNA‑lncRNA and mRNA‑lncRNA-pathway co‑expression networks based on WGCNA in developing pediatric sepsis
por: Zhang, Xiaojuan, et al.
Publicado: (2021)

Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
por: Zhu, Ying, et al.
Publicado: (2021)

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
por: Doi, Yohei
Publicado: (2019)

A Machine Learning Model for Accurate Prediction of Sepsis in ICU Patients
por: Wang, Dong, et al.
Publicado: (2021)

Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study
por: Wu, Zhenping, et al.
Publicado: (2023)

Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
por: Qu, Jian, et al.
Publicado: (2022)

Antimicrobial Peptides for Gram-Negative Sepsis: A Case for the Polymyxins
por: David, Sunil A.
Publicado: (2012)

Probing the Penetration of Antimicrobial Polymyxin Lipopeptides into Gram-Negative Bacteria
por: Deris, Zakuan Z., et al.
Publicado: (2014)

Low-dose polymyxin: an option for therapy of Gram-negative sepsis
por: Harm, Stephan, et al.
Publicado: (2016)

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
por: Bergen, Phillip J., et al.
Publicado: (2015)

Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics
por: Vaara, Martti
Publicado: (2019)

Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection
por: Xia, G. L., et al.
Publicado: (2023)

Bi-Functional Alginate Oligosaccharide–Polymyxin Conjugates for Improved Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Stokniene, Joana, et al.
Publicado: (2020)

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria
por: Lu, Jiayue, et al.
Publicado: (2022)

Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU
por: Yu, Jiaxin, et al.
Publicado: (2023)

Polymyxin E–Resistant Gram-Negative Bacteria in Tunisia and Neighboring Countries: Are There Commonalities?
por: Dziri, Olfa, et al.
Publicado: (2021)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

Adjunctive sepsis therapy with aminophylline (STAP): a randomized controlled trial
por: Zhang, Ruifang, et al.
Publicado: (2022)

Efficacy and safety of intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of multidrug-resistant gram-negative bacterial pneumonia: A systematic review and meta-analysis
por: Lu, Difan, et al.
Publicado: (2023)

690. Activity of a Novel Polymyxin Analog, QPX9003, Tested Against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas
por: Castanheira, Mariana, et al.
Publicado: (2019)

Evaluation and Validation of the Limited Sampling Strategy of Polymyxin B in Patients with Multidrug-Resistant Gram-Negative Infection
por: Li, Xueyong, et al.
Publicado: (2022)

Genetic Diversity of Polymyxin-Resistance Mechanisms in Clinical Isolates of Carbapenem-Resistant Klebsiella pneumoniae: a Multicenter Study in China
por: Li, Ziyao, et al.
Publicado: (2023)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
por: Nordmann, Patrice, et al.
Publicado: (2019)

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
por: Jean, Shio-Shin, et al.
Publicado: (2022)

SuperPolymyxin™ Medium for the Screening of Colistin-Resistant Gram-Negative Bacteria in Stool Samples
por: Przybysz, Sara M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t209r9a59tibrr1uils75j67kp